Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.48 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.45 |
| ▸ | LDHB | P07195 | 8/20 | 0.44 |
| ▸ | LDHA | P00338 | 8/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24137504 | 1.00 | HTR7 (0.48) | HTR7ASIC3LDHBLDHAADRA1D | |
| SCHEMBL24137799 | 0.82 | HTR7 (0.48) | HTR7LDHBLDHAADRA1DHTR2C | |
| SCHEMBL24137550 | 0.80 | HTR7 (0.50) | HTR7LDHBLDHAADRA1DHTR2C | |
| SCHEMBL24137472 | 0.78 | HTR7 (0.48) | HTR7LDHBLDHAADRA1DHTR2C | |
| SCHEMBL24137735 | 0.77 | LDHA (0.47) | HTR7LDHBLDHAADRA1DHTR2C | |
| SCHEMBL25937910 | 0.75 | HTR7 (0.51) | HTR7LDHBLDHAADRA1DHTR2C | |
| SCHEMBL24137805 | 0.75 | HTR7 (0.60) | HTR7LDHBLDHAADRA1DHTR2C | |
| SCHEMBL19237093 | 0.72 | TTK (0.52) | HTR7LDHBLDHAADRA1DHTR2C | |
| SCHEMBL22191525 | 0.71 | HTR7 (0.58) | HTR7LDHBLDHAADRA1DHTR2C | |
| SCHEMBL22191527 | 0.71 | HTR7 (0.58) | HTR7LDHBLDHAADRA1DHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | HTR7 2493/4885ASIC3 2131/4885LDHB 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.